ENOB Enochian Biosciences

Renovaro Biosciences Announces Results of Special Meeting of Shareholders

Renovaro Biosciences Announces Results of Special Meeting of Shareholders

LOS ANGELES, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB) (the “Company”), a biotechnology corporation focusing on cell, gene, and immunotherapy, announced today the results of the Company’s Special Meeting of Shareholders held at 12:00 pm ET on January 25, 2024.

All of the matters put forward before the Company's shareholders for consideration and approval, as set out in the Company's definitive proxy statement dated January 3, 2024, were approved by the requisite number of votes cast at the meeting.

For complete results on all matters voted on at the meeting, please consult the Company's Form 8-K which will be filed on EDGAR at .

ABOUT THE COMPANY

Renovaro has developed advanced cell, gene, and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases. For more information on Renovaro, go to their website at

Contact:

Source: Renovaro Bioscience Inc.



EN
25/01/2024

Underlying

ENOBEnochian Biosciences

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Enochian Biosciences

 PRESS RELEASE
Free
ENOB Enochian Biosci...

Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform

Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform New Proprietary Target Discovery and Validation Platform Integrates Multiomics, Contingent AI, Phenoclustering, and CRISPR Screens to Accelerate Drug Discovery LOS ANGELES, May 14, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), an AI-driven precision medicine company that leverages AI/ML platforms to improve outcomes for cancer and neurologically challenged patients, today announced it has launched Augusta, a Precision Neurology Platform for patient stratification, biomarker discovery, drug discovery, and valid...

May 14, 2025 1 EN
 PRESS RELEASE
Free
ENOB Enochian Biosci...

Renovaro and Amsterdam University Medical Center Announce Exclusive Co...

Renovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today agreed on terms for an exclusive collaboration agreement with Amsterdam University Medical Center (“Amsterdam UMC”) to jointly evaluate and develop blood platelet RNA diagnostics. This partnership marks an important step forward in the clinical validation and advancement o...

May 13, 2025 1 EN
 PRESS RELEASE
Free
ENOB Enochian Biosci...

Renovaro Secures High-Powered Computing from Nebul Through a Partnersh...

Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs LOS ANGELES, April 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), an AI-driven precision Medicine Company that leverages AI platforms to improve outcomes for cancer and neurologically challenged patients, today announced is expanding our ongoing strategic collaboration with Nebul (), a leading AI cloud infrastructure company, to advance the early detection of cancer and other diseases. The partnership aims to leverage Renovaro’s dee...

April 22, 2025 1 EN
 PRESS RELEASE
Free
ENOB Enochian Biosci...

Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomark...

Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine Strategic Combination Intended to Drive Advanced AI-Driven Drug Development and Expand Precision Medicine Applications Across Cancer and Neurology LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced it closed its merger transaction with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and precisio...

April 9, 2025 1 EN
 PRESS RELEASE
Free
ENOB Enochian Biosci...

Renovaro Provides Update to Definitive Agreement with Predictive Oncol...

Renovaro Provides Update to Definitive Agreement with Predictive Oncology LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today provided an update regarding its with Predictive Oncology Predictive Oncology, Inc. (NASDAQ: POAI) to initiate the integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States. Renovaro entered into a binding agreement merger agr...

April 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch